Penicillium marneffei is an important human immunodeficiency virus-associated opportunistic infection endemic in Southeast Asia. Central nervous system infection has not been described. We report the first case series of 21 human immunodeficiency virus-infected patients who presented with a syndrome consistent with acute central nervous system infection and who had Penicillium marneffei isolated from cerebrospinal fluid.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106247 | PMC |
| http://dx.doi.org/10.1086/657400 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Talaromyces marneffei central nervous system infection unveiled by the novel Mp1p antigen detection assay in AIDS patient.
BMC Infect Dis
December 2024
Central Laboratory, Chongqing Public Health Medical Centre, Chongqing, China.
Background: In acquired immunodeficiency syndrome patients, Talaromyces marneffei infections are mostly disseminated and may involve the skin, mucosa, respiratory system, digestive system, lymphatic system, and as some reports indicate, the nervous system. Mp1p, a cell wall-specific polysaccharide in Talaromyces marneffei, is used for laboratory diagnosis of Talaromyces marneffei in blood and urine samples. However, Cerebrospinal fluid Mp1p diagnosis of Talaromyces marneffei central nervous system infection has not been reported.
View Article and Find Full Text PDFThe Diagnosis of Talaromyces marneffei Central Nervous System Infection in an HIV-Negative Child by Cytological Assay of a Cerebrospinal Fluid Smear.
Mycopathologia
December 2024
Clinical Laboratory, Department of Clinical Laboratory, The People's Hospital of Longhua Shenzhen, Shenzhen, 518109, People's Republic of China.
Antifungal activity of bamemacrolactine C against Talaromyces marneffei and its possible mechanisms of action.
J Appl Microbiol
December 2024
Institute of Marine Drugs, Faculty of Pharmacy, Guangxi University of Chinese Medicine, No.13 Wuhe Road, Nanning 530200, China.
Aims: The present study aims to investigate the in vitro antifungal activity and mechanism of action of bamemacrolactine C (BAC), a new 24-membered macrolide compound, against Talaromyces marneffei.
Methods And Results: The test drug BAC initially demonstrated antifungal activity through a paper disk diffusion assay, followed by determination of the minimum inhibitory concentration value of 35.29 μg ml-1 using microdilution.
Prevalence of bone destruction in patients with TALAROMYCES MARNEFFEI infection: A systematic review and meta-analysis.
Int J Infect Dis
December 2024
College of Public Hygiene of Guangxi Medical University, Nanning, Guangxi, China.
Objectives: This systematic review and meta-analysis aimed to evaluate the prevalence of bone destruction in patients with Talaromyces marneffei infection, examine distribution patterns of bone lesions, and assess differences between HIV-positive and HIV-negative patients.
Methods: Following PRISMA guidelines, 15 studies involving 839 patients were analyzed. Random-effects meta-analysis was performed to estimate prevalence and odds ratios.
[ infection complicated by talaromycosis in a patient with positive anti-interferon-γ autoantibodies: a case report].
Zhonghua Jie He He Hu Xi Za Zhi
December 2024
Department of Respiratory and Critical Care Medicine, Fuzhou Provincial Hospital Affiliated to Fuzhou University, Fuzhou350001, China.
Article Synopsis
- - High levels of antibodies to interferon-gamma (IFN-γ) are linked to infections from intracellular pathogens, especially non-tuberculous mycobacteria (NTM) and tuberculosis (MTB).
- - The case study discusses a non-immunosuppressed patient who had both MTB infection and complications from NTM, which led to a severe condition called secondary hemophagocytic syndrome.
- - The report emphasizes the importance of recognizing this uncommon combination of infections to prevent misdiagnosis or unnecessary treatments for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!